

## Publications in peer-reviewed journals

1. Koumpis, E.; Papoudou-Bai, A.; Papathanasiou, K.; Kolettas, E.; Kanavaros, P.; **Hatzimichael, E.** Unraveling the Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic and Potential Therapeutic Implications. *Curr. Issues Mol. Biol.* 2024, 46, 7048-7064. <https://doi.org/10.3390/cimb46070420>
2. Dimitriadis, S.; Dova, L.; Kotsianidis, I.; **Hatzimichael, E.**; Kapsali, E.; Markopoulos, G.S. Imaging Flow Cytometry: Development, Present Applications, and Future Challenges. *Methods Protoc.* 2024, 7, 28. <https://doi.org/10.3390/mps7020028>
3. Papoudou-Bai, A.; Koumpis, E.; Karpathiou, G.; **Hatzimichael, E\***; Kanavaros, P\*. Expression Patterns of GATA3 in Classical Hodgkin Lymphoma: A Clinico-Pathological Study. *Diseases* 2024, 12, 51. <https://doi.org/10.3390/diseases12030051>, \* **equal contribution**
4. Georgoulis V, Koumpis E, **Hatzimichael E.** The Role of Non-Coding RNAs in Myelodysplastic Neoplasms. *Cancers (Basel)*. 2023 Sep 30;15(19):4810. doi: 10.3390/cancers15194810. PMID: 37835504
5. Vassilakopoulos TP, Piperidou A, Mellios Z, Verigou E, Katodritou E, Kalpadakis C, Papageorgiou SG, Chatzidimitriou C, Prassopoulos V, Siakantaris MP, Giatra H, Karantanis D, Papathanasiou N, Ligdi L, Kopsaftopoulou A, Leonidopoulou T, Xanthopoulos V, Karakatsanis S, Vrakidou E, Chatziioannou S, Drougkas D, **Hatzimichael E**, Gainaru G, Palassopoulou M, Tsirogianni M, Kotsopoulou M, Tsourouflis G, Skoura E, Mainta C, Terpos E, Poziopoulos C, Triantafyllou T, Zikos P, Koumariou A, Liapi D, Pappa V, Verrou E, Tsigotis P, Labropoulou V, Papadaki H, Datseris I, Symeonidis A, Bouzani M, Bakiri M, Karmiris T, Angelopoulou MK, Rondogianni P. PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated? *Hemasphere*. 2023 Nov 7;7(11):e965. PMID: 38027423
6. Bouchla A, Papageorgiou SG, Symeonidis A, Sakellari I, Zikos P, Thomopoulos TP, **Hatzimichael E**, Galanopoulos A, Vyniou NA, Kotsianidis I, Pappa V. Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome? *Leukemia*. 2023 Dec;37(12):2517-2519. doi: 10.1038/s41375-023-02051-3. Epub 2023 Oct 10.
7. Chatzikonstantinou T, Scarfò L, Karakatsoulis G, Minga E, Chamou D, Iacoboni G, Kotaskova J, Demosthenous C, Smolej L, Mulligan S, Alcoceba M, Al-Shemari S, Aurrán-Schleinitz T, Bacchiarri F, Bellido M, Bijou F, Calleja A, Medina A, Khan MA, Cassin R, Chatzileontiadou S, Collado R, Christian A, Davis Z, Dimou M, Donaldson D, Santos GD, Dreta B, Efstathopoulou M, El-Ashwah S, Enrico A, Fresa A, Galimberti S, Galitzia A, García-Serra R, Gimeno E, González-Gascón-Y-Marín I, Gozzetti A, Guarente V, Guieze R, Gogia A, Gupta R, Harrop S, **Hatzimichael E**, Herishanu Y, Hernández-Rivas JÁ, Inchiappa L, Jaksic O, Janssen S, Kalicińska E, Kamel L, Karakus V, Kater AP, Kho B, Kislova M, Konstantinou E, Koren-Michowitz M, Kotsianidis I,

Kreitman RJ, Labrador J, Lad D, Levin MD, Levy I, Longval T, Lopez-Garcia A, Marquet J, Martin-Rodríguez L, Maynadié M, Maslejova S, Mayor-Bastida C, Mihaljevic B, Milosevic I, Miras F, Moia R, Morawska M, Murru R, Nath UK, Navarro-Bailón A, Oliveira AC, Olivieri J, Oscier D, Panovska-Stavridis I, Papaioannou M, Papajík T, Kubova Z, Phumphukhiew P, Pierie C, Puiggros A, Rani L, Reda G, Rigolin GM, Ruchlemer R, Daniel de Deus Santos M, Schipani M, Schiwitz...Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. *EClinicalMedicine*. 2023 Nov 15;65:102307. doi: 10.1016/j.eclinm.2023.102307. eCollection 2023 Nov.

8. Koumpis E, Kyriazopoulou L, Tigas S, Kapsali E, **Hatzimichael E**. (July 07, 2023) Central Diabetes Insipidus in a Patient With Lymphoma: A Case Report. *Cureus* 15(7): e41500. doi:10.7759/cureus.41500
9. Georgoulis V, Papoudou-Bai A, Makis A, Kanavaros P, **Hatzimichael**, Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications. *Biology (Basel)*. 2023 Jun 15;12(6):862. doi: 10.3390/biology12060862.
10. Kanavos T, Birbas E, Papoudou-Bai A, **Hatzimichael E**, Kitsouli A, Karpathiou G, Kanavaros P. Primary Bone Lymphoma: A Review of the Literature with Emphasis on Histopathology and Histogenesis. *Diseases*. 2023 Mar 2;11(1):42. doi: 10.3390/diseases11010042.
11. Liapis K, Papadopoulos V, Pontikoglou C, Vrachiolias G, Stavroulaki E, Kourakli A, Lazaris V, Galanopoulos AG, Papoutselis M, Papageorgiou SG, Diamantopoulos PT, Pappa V, Viniou NA, Tsokanas D, Vassilakopoulos TP, **Hatzimichael E**, Bouronikou E, Ximeri M, Megalaki A, Zikos P, Panayiotidis P, Dimou M, Karakatsanis S, Papaioannou M, Papadakis S, Vardi A, Kontopidou F, Harchalakis N, Adamopoulos I, Symeonidis A, Papadaki HA, Kotsianidis I. Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries. *Leukemia*. 2023 Mar;37(3):708-711. doi: 10.1038/s41375-023-01819-x. Epub 2023 Jan 16.
12. Diamantopoulos PT, Solomou E, Symeonidis A, Pappa V, Kotsianidis I, Galanopoulos A, Pontikoglou C, Anagnostopoulos A, Vassilopoulos G, Zikos P, **Hatzimichael E**, Papaioannou M, Megalaki A, Vassilakopoulos T, Dimou M, Tsokanas D, Papoutselis MK, Papageorgiou S, Kourakli A, Papadaki H, Panayiotidis P, Viniou NA. The prognostic significance of macrocytosis in patients with myelodysplastic neoplasms. *Am J Hematol*. 2023 Feb 20. doi: 10.1002/ajh.26886. Online ahead of print.
13. Vassilakopoulos TP, Panitsas F, Mellios Z, Apostolidis J, Michael M, Gurion R, Ferhanoglu B, **Hatzimichael E**, Karakatsanis S, Dimou M, Kalpadakis C, Katodritou E, Leonidopoulou T, Kotsianidis I, Giatra H, Kanellias N, Sayyed A, Tadmor T, Akay OM, Angelopoulou MK, Horowitz N, Bakiri M, Pangalis GA, Panayiotidis P, Papageorgiou SG. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large b-cell lymphoma in the rituximab era. *Hematol Oncol*. 2022 Oct 31. doi: 10.1002/hon.3096
14. Diamantopoulos P, Charakopoulos E, Symeonidis A, Kotsianidis I, Viniou N-A, Pappa V, Pontikoglou Ch, Tsokanas D, Drakos G, Kourakli A, Solomou E, **Hatzimichael E**, Pouli A, Kotsopoulou M, Asmanis E, Dimou M, Panayiotidis P, Papageorgiou S, Vassilopoulos

- G, Anagnostopoulos A, Vassilakopoulos Th, Papadaki H, Galanopoulos G. Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome. *Sci Rep*. 2022 Oct 26;12(1):17914. doi: 10.1038/s41598-022-21933-7.
15. Georgoulis V, Haidich A-B, Bougioukas K, **Hatzimichael E**. Efficacy and safety of carfilzomib for the treatment of multiple myeloma: an overview of systematic reviews, *Crit Rev Hematol Oncol* <https://doi.org/10.1016/j.critrevonc.2022.103842>.
  16. **Hatzimichael E**, Timotheatou D, Koumpis E, Benetatos L, Makis A. Luspatercept: A New Tool for the Treatment of Anemia Related to  $\beta$ -Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis. *Diseases* 2022, 10, 85
  17. Kyriazopoulou L, Karpathiou G, **Hatzimichael E**, Peoc'h M, Papoudou-Bai A, Kanavaros P. Autophagy and cellular senescence in classical Hodgkin lymphoma. *Pathol Res Pract*. 2022 Jun 1;236:153964. doi: 10.1016/j.prp.2022.153964
  18. Karakatsanis SJ, Bouzani M, Symeonidis A, Angelopoulou MK, Papageorgiou SG, Michail M, Gainaru G, Kourti G, Sachanas S, Kalpadakis C, Katodritou E, Leonidopoulou T, Kotsianidis I, Hatzimichael E, Kotsopoulou M, Dimou M, Variamis E, Boutsis D, Kanellias N, Dimopoulou MN, Michali E, Karianakis G, Tsirkinidis P, Vadikolia C, Poziopoulos C, Pigaditou A, Vrakidou E, Economopoulos T, Kyriazopoulou L, Siakantaris MP, Kyrtsionis MC, Anargyrou K, Papaioannou M, Hatjiharissi E, Vervessou E, Tsirogianni M, Palassopoulou M, Stefanoudaki E, Zikos P, Tsigiotis P, Tsourouflis G, Assimakopoulou T, Verrou E, Papadaki H, Lampropoulou P, Dimopoulos MA, Pappa V, Konstantopoulos K, Karmiris T, Roussou P, Panayiotidis P, Pangalis GA, Vassilakopoulos TP; Hellenic Cooperative Lymphoma Group. Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. *In Vivo*. 2022 May-Jun;36(3):1302-1315. doi: 10.21873/invivo.12831.
  19. Barakos GP, **Hatzimichael E**. Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Diseases*. 2022; 10(2):33. <https://doi.org/10.3390/diseases10020033>
  20. Papakonstantinou I, Koumpis E, Fytsili E, Panteli A, Milionis H, Papoudou-Bai A, Kapsali E, **Hatzimichael E**. Leishmaniasis mimicking multiple myeloma. *Int J Lab Hematol* 2022 Feb;44(1):44-46. doi: 10.1111/ijlh.13667.
  21. E. Tzavella, L. Gika, **E. Hatzimichael**, H. Milionis, E. Liberopoulos Severe thrombocytopenia in COVID-19: a case report. *Journal of Atherosclerosis Prevention and Treatment, J Atherosclerosis Prev Treat*. 2021 May-Aug;12(2):51-54 | doi:10.53590/japt.02.1023
  22. Koumpis E, Tassi I, Malea T, Papathanasiou K, Papakonstantinou I, Serpanou A, Tsolas E, Kapsali E, Vassilakopoulos TP, Papoudou-Bai A, **Hatzimichael E**. CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome. *Pathol Res Pract*. 2021 Jul 28;225:153567. doi: 10.1016/j.prp.2021.153567. Online ahead of print.
  23. Makis A, Voskaridou E, Papassotiriou I, **Hatzimichael E**. Novel therapeutic advances in  $\beta$ -thalassemia. *Biology (Basel)* 2021 Jun 18;10(6):546
  24. Papakonstantinou I, Kosmidou M, Papathanasiou K, Koumpis E, Kapsali E, Milionis H, Vassilakopoulos TP, Papoudou-Bai A, **Hatzimichael E**. Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated

- With Brentuximab Vedotin: A Case Report and Review of the Literature. *In Vivo*. 2021 Jul-Aug;35(4):1951-1957. doi: 10.21873/invivo.12462.
25. Karakatsanis S; Hellenic Cooperative Lymphoma Group, Papageorgiou SG, Michail M, Angelopoulou MK, Kalpadakis C, Leonidopoulou T, Katodritou E, Kotsopoulou M, Kotsianidis I, Hatzimichael E, Lakiotaki E, Boutsis D, Karianakis G, Symeonidis A, Gavriatopoulou M, Panayiotidis P, Konstantopoulos K, Karmiris T, Pangalis GA, Vassilakopoulos TP. Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis. *Leuk Res*. 2021 Apr 24;107:106595. doi: 10.1016/j.leukres.2021.106595. Online ahead of print.
  26. Koumpis E, Papathanasiou K, Papakonstantinou I, Tassi I, Serpanou A, Kapsali E, **Hatzimichael E**. Rifampicin-induced thrombocytopenia: a case report and short review of the literature. *EMJ*. 2021; DOI/10.33590/emj/20-00193
  27. Liapis K, Papadopoulos V, Vrachiolias G, Galanopoulos AG, Papoutselis M, Papageorgiou SG, Diamantopoulos PT, Pappa V, Viniou NA, Kourakli A, Tsokanas D, Vassilakopoulos TP, **Hatzimichael E**, Bouronikou E, Ximeri M, Pontikoglou C, Megalakaki A, Zikos P, Panayiotidis P, Dimou M, Karakatsanis S, Papaioannou M, Vardi A, Kontopidou F, Harchalakis N, Adamopoulos I, Symeonidis A, Kotsianidis I. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes. *Blood Cancer J*. 2021 Feb 11;11(2):30. doi: 10.1038/s41408-021-00424-4
  28. Dimou M, Papageorgiou SG, Stavroyianni N, Katodritou E, Tsirogianni M, Kalpadakis C, Banti A, Arapaki M, Iliakis Th, Bouzani M, Verrou E, Spanoudakis E, Giannouli S, Marinakis Th, Mandala E, Mparmparousi D, Sachanas S, Dalekou-Tsolakou M, **Hatzimichael E**, Vadikolia Ch, Violaki V, Poziopoulos C, Tsirkinidis P, Chatzileontiadou S, Vervessou E, Ximeri M, Sioni A, Konstantinidou P, Kyrtsionis M-C, Siakantaris M, Angelopoulou MK, Pappa V, Konstantopoulos K, Panayiotidis P, Vassilakopoulos TP. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. *Hematol Oncol* 2021 Feb 13. doi: 10.1002/hon.2842. Online ahead of print.
  29. Vassilakopoulos TP, Michail M, Papageorgiou S, Kourti G, Angelopoulou MK, Panitsas F, Sachanas S, Kalpadakis C, Katodritou E, Leonidopoulou T, Kotsianidis I, **Hatzimichael E**, Kotsopoulou M, Dimou M, Variamis E, Boutsis D, Terpos E, Dimopoulou MN, Karakatsanis S, Michali E, Karianakis G, Tsirkinidis P, Vadikolia C, Poziopoulos C, Pigaditou A, Vrakidou E, Economopoulos T, Kyriazopoulou L, Siakantaris MP, Kyrtsionis MC, Symeonidis A, Anargyrou K, Papaioannou M, Chatziharissi E, Vervessou E, Tsirogianni M, Palassopoulou M, Gainaru G, Stefanoudaki E, Zikos P, Tsirigotis P, Tsourouflis G, Assimakopoulou T, Konstantinidou P, Papadaki H, Megalakaki K, Dimopoulos MA, Pappa V, Karmiris T, Roussou P, Panayiotidis P, Konstantopoulos K, Pangalis GA. Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. *Oncologist* 2021 doi: 10.1002/onco.13789. Online ahead of print.
  30. Vassilakopoulos TP, Papageorgiou SG, Angelopoulou MK, Chatziioannou S, Prassopoulos V, Karakatsanis S, Arapaki M, Mellios Z, Sachanas S, Kalpadakis C,

- Katodritou E, Leonidopoulou T, Kotsianidis I, **Hatzimichael E**, Kotsopoulou M, Dimou M, Variamis E, Boutsis D, Terpos E, Michali E, Karianakis G, Tsirkinidis P, Vadikolia C, Poziopoulos C, Pigaditou A, Vrakidou E, Siakantaris MP, Kyrtsolis MC, Symeonidis A, Anargyrou K, Papaioannou M, Chatziharissi E, Vervessou E, Tsirogianni M, Palassopoulou M, Gainaru G, Mainta C, Tsirigotis P, Assimakopoulou T, Konstantinidou P, Papadaki H, Dimopoulos MA, Pappa V, Karmiris T, Roussou P, Datseris I, Panayiotidis P, Konstantopoulos K, Pangalis GA, Rondogianni P. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. *Ann Hematol.* 2021 Feb 1. doi: 10.1007/s00277-021-04421-2. Online ahead of print.
31. Papageorgiou S.G, Kotsianidis I., Bouchla A., Symeonidis A., Galanopoulos A., Viniou N-A, **Hatzimichael E.**, Vassilakopoulos T.P, Gogos D., Megalakaki A., Zikos P., Diamantopoulos P., Kourakli A., Giannoulia P., Papoutselis M., Poulakidas E., Arapaki M., Vardi A, Anagnostopoulos A., Mparmparousi D., Papaioannou M., Bouronikou E., Dimou M., Papadaki H., Panayiotidis P., Pappa V. Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. *Ther Adv Hematol.* 2020 Dec 8;11 doi: 10.1177/2040620720966121
32. Vassilakopoulos TP, Piperidou A, Hadjiharissi E, Panteliadou AK, Panitsas F, Vassilopoulos I, Variamis E, Boutsis D, Michail M, Papageorgiou S, Tsourouflis G, Dimou M, Karakatsanis S, Kalpadakis C, Stavroyianni N, Katodritou E, Kotsopoulou M, Kotsianidis I, Verigou E, **Hatzimichael E**, Leonidopoulou T, Xanthopoulos V, Panayiotidis P, Konstantopoulos K, Dimopoulos MA, Karmiris T, Batsis I, Papaioannou M, Pangalis GA, Angelopoulou MK. Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database. *Leuk Res.* 2020 Nov 16;100:106479. doi: 10.1016/j.leukres.2020.106479. Online ahead of print.
33. Koumpis E, Florentin M, **Hatzimichael E**, Liamis G. Hyponatremia in Patients with Hematologic Diseases. *J Clin Med.* 2020 Nov 19;9(11):3721. doi: .3390/jcm9113721.PMID: 33228240
34. Pomoni A, Aggeli I, Loutsi E, **Hatzimichael E**, Chaliasos N, Makis A. Cyanosis Due to Methemoglobinemia as the Presenting Sign of Glucose-6-Phosphate Dehydrogenase Deficiency in a Child: Diagnostic and Clinical Implications. *J Pediatr Hematol Oncol.* 2020 Oct 7. doi: 10.1097/MPH.0000000000001967.
35. Hoeks M, Bagguley T, van Marrewijk C, Smith A, Bowen D, Culligan D, Kolade S, Symeonidis A, Garelius H, Spanoudakis M, Langemeijer S, Roelofs R, Wiegerinck E, Tatic A, Killick S, Panayiotidis P, Stanca O, Hellström-Lindberg E, Cermak J, van der Klauw M, Wouters H, van Kraaij M, Blijlevens N, Swinkels DW, de Witte T; EUMDS Registry Participants. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome. *Leukemia.* 2021 Jun;35(6):1745-1750. doi: 10.1038/s41375-020-01022-2. Epub 2020 Sep 18.

36. Prieto JC, Vallejo Casas JA, **Hatzimichael E**, Fotopoulos A, Kiortsis DN, Sioka C. The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas. *Ann Nucl Med*. 2020 Oct;34(10):707-717. doi: 10.1007/s12149-020-01521-3.
37. Diamantopoulos PT, Symeonidis A, Pappa V, Kotsianidis I, Galanopoulos A, Pontikoglou C, Anagnostopoulos A, Vassilopoulos G, Zikos P, **Hatzimichael E**, Papaioannou M, Megalakaki A, Repousis P, Kotsopoulou M, Dimou M, Solomou E, Dryllis G, Tsokanas D, Papoutselis MK, Papageorgiou S, Kyrtsionis MC, Kourakli A, Papadaki H, Panayiotidis P, Viniou NA. The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes. *Br J Haematol*. 2020 Aug 30. doi: 10.1111/bjh.17062. Online ahead of print. PMID: 3286244
38. Papadopoulos V, Diamantopoulos PT, Papageorgiou SG, Papoutselis M, Vrachioliass G, Pappa V, Galanopoulos AG, Vassilakopoulos TP, **Hatzimichael E**, Zikos P, Papadak HA, Bouchla A, Panayiotidis P, Megalakaki A, Papaioannou M, Liapis K, Dryllis G, Tsokanas D, Kourakli A, Symeonidis, A Viniou NA, Kotsianidis I. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic Syndromes. *Hematological Oncology* 2020 Jun.
39. Diamantopoulos PT, Pappa V, Symeonidis A, Kotsianidis I, Galanopoulos A, Papadaki H, Anagnostopoulos A, Vassilopoulos G, Zikos P, **Hatzimichael E**, Papaioannou M, Megalakaki A, Kotsopoulou M, Repousis P, Dimou M, Solomou E, Pontikoglou C, Kyriakakis G, Tsokanas D, Papoutselis MK, Papageorgiou S, Kourakli A, Panayiotidis P, Viniou NA. Characteristics of Long-Term Survival in Patients with Myelodysplastic Syndrome Treated With 5-Azacitidine: Results From the Hellenic 5-Azacitidine Registry. *Clin Lymphoma Myeloma Leuk*. 2020 Feb;20(2):114-121.
40. Makis A, Georgiou I, Traeger-Synodinos J, Storino MR, Giuliano M, Andolfo I, **Hatzimichael E**, Chaliasos N, Giapros V, Izzo P, Iolascon A, Grosso M. A Novel  $\epsilon\delta\beta$ -Thalassemia Deletion Associated with Severe Anemia at Birth and a  $\beta$ -Thalassemia Intermedia Phenotype Later in Life in Three Generations of a Greek Family. *Hemoglobin*. 2019 Dec 12:1-4.
41. Papageorgiou SG, Kontos CK, Kotsianidis I, Karousi P, Symeonidis A, Galanopoulos A, Bouchla A, **Hatzimichael E**, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V. Effectiveness of 5-Azacitidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group. *J Geriatr Oncol*. 2020 Jan;11(1):121-124
42. Diamantopoulos P, Koumbi D, Kotsianidis I, Pappa V, Symeonidis A, Galanopoulos A, Zikos P, Papadaki HA, Panayiotidis P, Dimou M, **Hatzimichael E**, Vassilopoulos G, Delimpasis S, Mparmparousi D, Papageorgiou S, Variami E, Kyrtsionis MC, Megalakaki A, Kotsopoulou M, Repousis P, Adamopoulos I, Kontopidou F, Christoulas D, Kourakli A, Tsokanas D, Konstantinos Papoutselis M, Kyriakakis G, Viniou NA; Hellenic MDS study group. The prognostic significance of chromosome 17 abnormalities in patients with

myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry. *Cancer Med.* 2019 May;8(5):2056-2063.

43. Tsolkas G, Komninou D, Briasoulis E, **Hatzimichael E**, Papanikolaou NA. A Novel Therapeutic Approach in Acute Promyelocytic Leukemia with All-trans retinoic Acid and Cyclin-dependent Kinase Inhibitors. *Clin Cancer Drugs* 2018;5: 50-59
44. Diamantopoulos PT, Kotsianidis I, Symeonidis A, Pappa V, Galanopoulos A, Gogos D, Karakatsanis S, Papadaki H, Palla A, **Hatzimichael E**, Dimou M, Papageorgiou S, Delimpasis S, Papaioannou M, Papoutselis M, Kourakli A, Tsokanas D, Anagnostopoulos A, Kontos CK, Panayiotidis P, Viniou NA; Hellenic MDS study group. Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. *Leuk Lymphoma.* 2018 Nov 14:1-10. [Epub ahead of print]
45. Papageorgiou SG, Kontos CK, Kotsianidis I, Vasilatou D, Symeonidis A, Galanopoulos A, Bouchla A, **Hatzimichael E**, Repousis P, Zikos P, Viniou NA, Poulakidas E, Vassilakopoulos TP, Diamantopoulos P, Diamantopoulos MA, Mparmparousi D, Bouronikou E, Papadaki H, Panayiotidis P, Pappa V. The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. *Hematol Oncol.* 2018 Aug 20. doi: 10.1002/hon.2551. [Epub ahead of print]
46. Papageorgiou SG, Kotsianidis I, Kontos CK, Symeonidis A, Galanopoulos A, **Hatzimichael E**, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Bouronikou E, Panayiotidis P, Viniou NA, Pappa V. Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group. *Leuk Res.* 2018 Jul 7;71:55-59. doi: 10.1016/j.leukres.2018.07.004.
47. Katodritou E, Kyrtonis MC, Delimpasi S, Kyriakou D, Symeonidis A, Spanoudakis E, Vasilopoulos G, Anagnostopoulos A, Kioumi A, Zikos P, Aktypi A, Briasoulis E, Megalaki A, Repousis P, Adamopoulos I, Gogos D, Kotsopoulou M, Pappa V, Papadaki E, Fotiou D, Nikolaou E, Giannopoulou E, **Hatzimichael E**, Giannakoulas N, Douka V, Kokoviadou K, Timotheatou D, Terpos E. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. *Ann Hematol.* 2018 Jun 26.
48. Tsirigotis P, Vassilakopoulos T, Batsis I, Bousiou Z, Gkirkas K, Sakellari I, Kaloyannidis P, Roussou P, Pangalis GA, Moschogiannis M, Vassilopoulos G, Repousis P, Megalaki A, Michalis E, Kalpadakis C, Papadaki HA, Kotsianidis I, **Hatzimichael E**, Spyridonidis A, Anargyrou K, Poulakidas E, Giannoullia P, Apostolidis I, Stamouli M, Konstantopoulos K, Pappa V, Panayiotidis P, Harhalakis N, Anagnostopoulos A, Angelopoulou M. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis. *Hematol Oncol.* 2018 Jun 8. doi: 10.1002/hon.2521.
49. Papageorgiou SG, Vasilatou D, Kontos CK, Kotsianidis I, Symeonidis A, Galanopoulos AG, **Hatzimichael E**, Megalaki A, Poulakidas E, Diamantopoulos P, Vassilakopoulos TP, Zikos P, Papadaki H, Mparmparousi D, Bouronikou E, Panayiotidis P, Viniou NA,

- Pappa V. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. *Am J Hematol*. 2018 Jul;93(7):895-901. doi: 10.1002/ajh.25111. Epub 2018 May 16.
50. Makis A, Gkoutisias A, Palianopoulos T, Pappa E, Papapetrou E, Tsaousi C, **Hatzimichael E**, Chaliasos N. Prognostic Factors for Immune Thrombocytopenia Outcome in Greek Children: A Retrospective Single-Centered Analysis. *Adv Hematol*. 2017:7878605
51. **E. Hatzimichael**, K. Papathanasiou, I. Zerdes, S. Flindris, A. Papoudou-Bai, E. Kapsali. Plasmablastic lymphoma with coexistence of chronic lymphocytic leukemia in an immunocompetent patient: A case report and mini-review. *Case Rep Hematol* 2017: 2861956
52. Zagouri F, Kastritis E, Zomas A, Terpos E, Katodritou E, Symeonidis A, Delimpasi S, Pouli A, Vassilakopoulos TP, Michalis E, Giannouli S, Kartasis Z, Christoforidou A, Kokoviadou K, Hatzimichael E, Gika D, Megalakaki C, Papaioannou M, Kyrtsolis MC, Konstantopoulos K, Dimopoulos MA; Greek Myeloma Study Group. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. *Eur J Haematol*. 2017 Nov;99(5):409-414. doi: 10.1111/ejh.12923. Epub 2017 Sep 26. PMID: 2867576

-----*εκλογή σε θέση Επίκουρης Καθηγήτριας Αιματολογίας επί θητεία*

53. Tzavella E, **Hatzimichael E**, Kostara C, Bairaktari E, Elisaf M, Tsimihodimos V. Sitosterolemia: A multifaceted metabolic disorder with important clinical consequences. *J Clin Lipidol*. 2017 [Epub ahead of print]
54. Lambri E, Sainis I, Kounnis I, Mistelou A, Ioachim E, **Hatzimichael E**, Galani V, Briasoulis E. SLCO1B3 screening in colorectal cancer patients using High-Resolution Melting Analysis method and immunohistochemistry. *Tumour Biol*. 2017 Mar;39(3) DOI [10.1177/1010428317691176](https://doi.org/10.1177/1010428317691176)
55. Angelopoulou MK, Vassilakopoulos TP, Batsis I, Sakellari I, Gkirkas K, Pappa V, Giannoulia P, Apostolidis I, Apostolopoulos C, Roussou P, Panayiotidis P, Dimou M, Kyrtsolis MC, Palassopoulou M, Vassilopoulos G, Moschogiannis M, Kalpadakis C, Margaritis D, Spyridonidis A, Michalis E, Anargyrou K, Repousis P, **Hatzimichael E**, Bousiou Z, Poulakidas E, Grentzelias D, Harhalakis N, Pangalis GA, Anagnostopoulos A, Tsirigotis P. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. *Hematol Oncol*. 2017 Feb 20. doi: 10.1002/hon.2383. [Epub ahead of print]
56. Biziota E, Mavroiedis L, **Hatzimichael E**, Pappas P. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. *Cancer Lett* 2016 (epub ahead of print).
57. Makis A, **Hatzimichael E**, Papassotiriou I, Voskaridou E. 2017 Clinical trials update in new treatments of  $\beta$ -thalassemia. *Am J Hematol* 2016 Nov;91(11):1135-1145



58. Papoudou-Bai A, **Hatzimichael E**, Barbouti A, Kanavaros P. Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms. *Clin Exp Med*. 2016 Sep 6. [Epub ahead of print]
59. **Hatzimichael E**, Lagos K, Vassou A, Gougopoulou D, Papoudou-Bai A, Briasoulis E. Durable hematologic response to lenalidomide in a patient with isolated del(5q) MDS and JAK2V617F mutation despite discontinuation of treatment. *Mol Clin Oncol*, 2016; 5: 23-26
60. **Hatzimichael E**, Briasoulis E. Megaloblastic anemia presenting with skin hyperpigmentation. *International Journal of Hematology*, 2016; 103(5):479-80
61. Papoudou-Bai A, **Hatzimichael E**, Kyriazopoulou L, Briasoulis E, Kanavaros P. Rare variants in the spectrum of human herpesvirus 8/Epstein-Barr virus-copositive lymphoproliferations. *Hum Pathol*. 2015 Oct;46(10):1566-71.
62. Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, **Hatzimichael E**, Kirino Y, Honda S, Lally M, Ramratnam B, Comstock CE, Knudsen KE, Gomella L, Spaeth GL, Hark L, Katz LJ, Witkiewicz A, Rostami A, Jimenez SA, Hollingsworth MA, Yeh JJ, Shaw CA, McKenzie SE, Bray P, Nelson PT, Zupo S, Van Roosbroeck K, Keating MJ, Calin GA, Yeo C, Jimbo M, Cozzitorto J, Brody JR, Delgrosso K, Mattick JS, Fortina P, Rigoutsos I. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. *Proc Natl Acad Sci U S A*. 2015 Mar 10;112(10):E1106-15
63. **Hatzimichael E**, Lagos K, Sim VR, Briasoulis E, Crook T. Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update. *EXCLI Journal* 2014;13:954-976
64. Primikyri A, Chatziathanasiadou MV, Karali E, Kostaras E, Mantzaris MD, **Hatzimichael E**, Shin JS, Chi SW, Briasoulis E, Kolettas E, Gerothanassis IP, Tzakos AG. Direct binding of bcl-2 family proteins by quercetin triggers its pro-apoptotic activity. *ACS Chem Biol*. 2014 Dec 19;9(12):2737-41.
65. **Hatzimichael E**, Tsolas E, Briasoulis E. Profile of pacritinib and its potential in the treatment of hematologic disorders. *J Blood Med*. 2014 Aug 19;5:143-52.
66. Benetatos L, Vartholomatos G, **Hatzimichael E**. DLK1-DIO3 imprinted cluster in induced pluripotency: landscape in the mist. *Cell Mol Life Sci*. 2014 Nov;71(22):4421-30.
67. Benetatos L, **Hatzimichael E**. Delta-Like Homologue 1 and Its Role in the Bone Marrow Niche and Hematologic Malignancies. *Clin Lymphoma Myeloma Leuk*. 2014 Dec;14(6):451-455.
68. **Hatzimichael E**, Syed N, Lo Nigro C, Rao B, Crook T. How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis. *Expert Rev Mol Diagn*. 2014 Jul;14(6):639-42.
69. **Hatzimichael E**, Syed N., Lo Nigro C, Crook T. A blood test to identify when melanoma metastasizes: a reality for melanoma management? *Melanoma Management* (2014) 1(1), 11–14
70. Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A, Delimpasi S, Katodritou E, Michalis E, Michael M, **Hatzimichael E**, Vassou A, Repousis P, Christophoridou A, Kartasis Z, Stefanoudaki E, Megalakaki C, Giannouli S, Kyrtsionis MC, Konstantopoulos K, Spyropoulou-Vlachou M, Terpos E, Dimopoulos MA; Greek

Myeloma Study Group. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. *Leukemia*. 2014 Oct;28(10):2075-9.

71. Londin ER, **Hatzimichael E**, Loher P, Edelstein L, Shaw C, Delgrosso K, Fortina P, Bray PF, McKenzie SE, Rigoutsos I. The human platelet: strong transcriptome correlations among individuals associate weakly with the platelet proteome. *Biol Direct*. 2014 Feb 14;9:3
72. **Hatzimichael E**, Briasoulis E. Metronomic chemotherapy beyond misconceptions. *Haematologica*. 2013 Nov;98(11):e145.
73. Benetatos L, Vartholomatos G, **Hatzimichael E**. Polycomb group proteins and MYC: the cancer connection. *Cell Mol Life Sci*. 2014 Jan;71(2):257-69.
74. Katodritou E, Vadikolia C, Lalagianni C, Kotsopoulou M, Papageorgiou G, Kyrtsolis MC, Matsouka P, Giannakoulas N, Kyriakou D, Karras G, Anagnostopoulos N, Michali E, Briasoulis E, **Hatzimichael E**, Spanoudakis E, Zikos P, Tsakiridou A, TSIONOS K, Anargyrou K, Symeonidis A, Maniatis A, Terpos E. "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. *Ann Hematol*. 2014 Jan;93(1):129-39
75. Makis A, Challa A, **Hatzimichael E**, Briasoulis E, Siamopoulou A, Chaliasos N. Adipocytokines are related to haemolytic and inflammatory biomarkers in sickle cell beta thalassaemia. *Br J Haematol*. 2013 Oct;163(1):142-4.
76. **Hatzimichael E**, Murray S, Briasoulis E. Absence of BRAF exon 15 mutations in multiple myeloma and Waldenström's macroglobulinemia questions its validity as a therapeutic target in plasma cell neoplasias. *Am J Blood Res*. 2013
77. **Hatzimichael E**, Crook T. Cancer epigenetics: new therapies and new challenges. *J Drug Deliv*. 2013;2013:529312
78. Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, **Hatzimichael E**, Briasoulis E, Merlano M, Evans A, Thompson A, Leigh I, Fleming C, Inman GJ, Proby C, Crook T. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. *J Invest Dermatol*. 2013 May;133(5):1278-85
79. **Hatzimichael E**, Georgiou G, Benetatos L, Briasoulis E. Gene mutations and molecularly targeted therapies in acute myeloid leukemia. *Am J Blood Res*. 2013;3(1):29-51
80. Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, **Hatzimichael E**, Bomalaski J, Szlosarek P, Awad M, O'Neil K, Roncaroli F, Crook T. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. *Cell Death Dis*. 2013 Jan 17;4:e458
81. Froudarakis M\*, **Hatzimichael E\***, Kyriazopoulou L, Lagos K, Pappas P, Tzakos AG, Karavasilis V, Daliani D, Papandreou C, Briasoulis E. Revisiting bleomycin from pathophysiology to safe clinical use. *Crit Rev Oncol Hematol*. 2013 Jul;87(1):90-100  
**\*equal contribution**
82. Dranitsaris G, Dorward K, **Hatzimichael E**, Amir E. Clinical trial design in biosimilar drug development. *Invest New Drugs*. 2013 Apr;31(2):479-87.

83. Benetatos L, Voulgaris E, Vartholomatos G, **Hatzimichael E**. Non-coding RNAs and EZH2 interactions in cancer: long and short tales from the transcriptome. *Int J Cancer*. 2013 Jul 15;133(2):267-74
84. **Hatzimichael E**, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D, Monteverde M, Merlano M, Papoudou-Bai A, Bai M, Schmid P, Stebbing J, Bower M, Dyer MJ, Karran LE, ElguetaKarstegl C, Farrell PJ, Thompson A, Briasoulis E, Crook T. The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. *Br J Cancer*. 2012 Oct 9;107(8):1423-32.
85. Benetatos L, **Hatzimichael E**, Londin E, Vartholomatos G, Loher P, Rigoutsos I, Briasoulis E. The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis. *Cell Mol Life Sci*. 2013 Mar;70(5):795-814
86. Delage B, Luong P, Maharaj L, O'Riain C, Syed N, Crook T, **Hatzimichael E**, Papoudou-Bai A, Mitchell TJ, Whittaker SJ, Cerio R, Gribben J, Lemoine N, Bomalaski J, Li CF, Joel S, Fitzgibbon J, Chen LT, Szlosarek PW. Promoter methylation of arginosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. *Cell Death Dis* 2012; 5:e342
87. Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, Harwood C, Syed N, Szlosarek P, Briasoulis E, McHugh A, Thompson A, Evans A, Leigh I, Fleming C, Inman GJ, **Hatzimichael E**, Proby C, Crook T. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. *Br J Cancer* 2012;106:1446-1452.
88. Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, **Hatzimichael E**, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T. NT5E CpG island methylation is a favourable breast cancer biomarker. *Br J Cancer* 2012;107:75-83.
89. **Hatzimichael E**, Dasoula A, Kounnis V, Benetatos L, Nigro CL, Lattanzio L, Papoudou-Bai A, Dranitsaris G, Briasoulis E, Crook T. Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications. *Leuk Lymphoma* 2012.
90. Dranitsaris G, **Hatzimichael E**. Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. *Support Care Cancer* 2012;20:1353-1360.
91. Dimopoulos MA, Kastiris E, Delimpasi S, Katodritou E, **Hatzimichael E**, Kyrtsolis MC, Repousis P, Tsirogianni M, Kartasis Z, Parcharidou A, Michael M, Michalis E, Tsatalas C, Stefanoudaki E, Hatjiharissi E, Gika D, Symeonidis A, Terpos E, Zervas K. Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era. *Eur J Haematol* 2012;89:10-15.
92. Coley HM, **Hatzimichael E**, Blagden S, McNeish I, Thompson A, Crook T, Syed N. Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer. *Oncotarget* 2012;3:78-83.
93. Tzakos AG, Fokas D, Johannes C, Moussis V, **Hatzimichael E**, Briasoulis E. Targeting oncogenic protein-protein interactions by diversity oriented synthesis and combinatorial chemistry approaches. *Molecules* 2011;16:4408-4427.

94. Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P, McNeish I, Blagden SP, Schmid P, Lovell DP, **Hatzimichael E**, Crook T. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. *Cancer Res* 2011;71:3317-3327.
95. **Hatzimichael E**, Kapsali, E. Crook, T. Tuthill, M. The role of Plerixafor in the management of Non-Hodgkin's Lymphoma. *Clin Med Rev Oncol* 2011;3.
96. **Hatzimichael E**, Briasoulis, E. Attitudes of people, authorities and doctors towards clinical cancer research: high expectations, neglected responsibilities and minimal involvement outline a hazy picture. Can we do any better? *Mediterranean Oncol J* 2011;1:9-13.
97. Benetatos L, Vartholomatos G, **Hatzimichael E**. MEG3 imprinted gene contribution in tumorigenesis. *Int J Cancer* 2011;129:773-779.
98. Benetatos L, Dasoula A, **Hatzimichael E**, Syed N, Voukelatou M, Dranitsaris G, Bourantas KL, Crook T. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. *Ann Hematol* 2011;90:1037-1045.
99. Ximeri M, Galanopoulos A, Klaus M, Parcharidou A, Giannikou K, Psyllaki M, Symeonidis A, Pappa V, Kartasis Z, Liapi D, **Hatzimichael E**, Kokoris S, Korkolopoulou P, Sambani C, Pontikoglou C, Papadaki HA. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. *Haematologica* 2010;95:406-414
100. Makis A, Shipway D, **Hatzimichael E**, Galanakis E, Pshezhetskiy D, Chaliasos N, Stebbing J, Siamopoulou A. Cytokine and adhesion molecule expression evolves between the neutrophilic and lymphocytic phases of viral meningitis. *J Interferon Cytokine Res* 2010;30:661-665.
101. Lee S, Syed N, Taylor J, Smith P, Griffin B, Baens M, Bai M, Bourantas K, Stebbing J, Naresh K, Nelson M, Tuthill M, Bower M, **Hatzimichael E**, Crook T. DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt's lymphoma. *Br J Cancer* 2010;103:265-274.
102. **Hatzimichael E**, Tuthill, M. Hematopoietic stem cell transplantation. *Stem Cells Cloning* 2010:105-117.
103. **Hatzimichael E**, Dasoula A, Shah R, Syed N, Papoudou-Bai A, Coley HM, Dranitsaris G, Bourantas KL, Stebbing J, Crook T. The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. *Eur J Haematol* 2010;84:47-51.
104. **Hatzimichael E**, Dasoula A, Benetatos L, Syed N, Dranitsaris G, Crook T, Bourantas K. Study of specific genetic and epigenetic variables in multiple myeloma. *Leuk Lymphoma* 2010;51:2270-2274.
105. Chaliasos N, Challa A, **Hatzimichael E**, Koutsouka F, Bourantas DK, Vlahos AP, Siamopoulou A, Bourantas KL, Makis A. Serum adipocytokine and vascular inflammation marker levels in Beta-thalassaemia major patients. *Acta Haematol* 2010;124:191-196.
106. Benetatos L, **Hatzimichael E**, Dasoula A, Dranitsaris G, Tsiara S, Syrrou M, Georgiou I, Bourantas KL. CpG methylation analysis of the MEG3 and SNRPN imprinted

- genes in acute myeloid leukemia and myelodysplastic syndromes. *Leuk Res* 2010;34:148-153.\***equal contribution**
107. Powles T, Stebbing J, Bazeos A, **Hatzimichael E**, Mandalia S, Nelson M, Gazzard B, Bower M. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. *Ann Oncol* 2009;20:775-779.
  108. **Hatzimichael E**, Dranitsaris G, Dasoula A, Benetatos L, Stebbing J, Crook T, Bourantas KL. Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease. *Clin Lymphoma Myeloma* 2009;9:239-242.
  109. **Hatzimichael E**, Benetatos L, Dasoula A, Dranitsaris G, Tsiara S, Georgiou I, Syrrou M, Stebbing J, Coley HM, Crook T, Bourantas KL. Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia. *Leuk Res* 2009;33:1272-1275.
  110. **Hatzimichael E**, Dasoula A, Benetatos L, Makis A, Stebbing J, Crook T, Syrrou M, Bourantas KL. The absence of CDKN1C (p57KIP2) promoter methylation in myeloid malignancies also characterizes plasma cell neoplasms. *Br J Haematol* 2008;141:557-558.
  111. Descamps M, **Hatzimichael E**, Bhuva N, Stebbing J. Radiological imaging in the context of HIV infection: size of the lesion is not everything. *J HIV Ther* 2008;13:47-48.
  112. Benetatos L, Dasoula A, Syed N, **Hatzimichael E**, Crook T, Bourantas KL. Methylation analysis of the von Hippel-Lindau gene in acute myeloid leukaemia and myelodysplastic syndromes. *Leukemia* 2008;22:1293-1295
  113. Benetatos L, Dasoula A, **Hatzimichael E**, Georgiou I, Syrrou M, Bourantas KL. Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. *Clin Lymphoma Myeloma* 2008;8:171-175
  114. Panteli K, Bai M, **Hatzimichael E**, Zagorianakou N, Agnantis NJ, Bourantas K. Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases. *Hematology* 2007;12:481-486.
  115. Benetatos L, **Hatzimichael E**, Vassou A, Bourantas KL. Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient. *Leuk Res* 2007;31:119-120.
  116. Winston A, **Hatzimichael E**, Marvin V, Stebbing J, Bower M. Host pharmacogenetics in the treatment of HIV and cancer. *Curr Drug Saf* 2006;1:107-116.
  117. Stebbing J, Mazhar D, Lewis R, Palmieri C, **Hatzimichael E**, Nelson M, Gazzard B, Bower M. The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma. *Ann Oncol* 2006;17:503-506.
  118. Makis AC, **Hatzimichael E**, Stebbing J, Bourantas KL. C-reactive protein and vascular cell adhesion molecule-1 as markers of severity in sickle cell disease. *Arch Intern Med* 2006;166:366-368.
  119. Makis AC, **Hatzimichael E**, Stebbing J. The genomics of new drugs in sickle cell disease. *Pharmacogenomics* 2006;7:909-917.

120. **Hatzimichael E**, Benetatos L, Stebbing J, Kapsali E, Panayiotopoulou S, Bourantas KL. Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support. *Clin Lab Haematol* 2006;28:416-418.
121. Stebbing J, **Hatzimichael E**, Bower M, Winston A. The rationale and development of new drugs to treat HIV infection. *Med Chem* 2005;1:635-642.
122. Sfagos C, Makis AC, Chaidos A, **Hatzimichael EC**, Dalamaga A, Kosma K, Bourantas KL. Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients. *Mult Scler* 2005;11:272-275.
123. Panteli KE, **Hatzimichael E**, Bouranta PK, Katsaraki A, Seferiadis K, Stebbing J, Bourantas KL. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. *Br J Haematol* 2005;130:709-715.
124. Makis AC, Galanakis E, **Hatzimichael E**, Papadopoulou ZL, Siamopoulou A, Bourantas KL. Serum levels of soluble interleukin-2 receptor alpha (sIL-2Ralpha) as a predictor of outcome in brucellosis. *J Infect* 2005;51:206-210.
125. Makis AC, **Hatzimichael E**, Kolios G, Bourantas KL. Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment. *Haematologica* 2004;89:360-361.
126. Chaidos A, Makis A, **Hatzimichael E**, Tsiara S, Gouva M, Tzouvara E, Bourantas KL. Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. *Acta Haematologica* 2004;111:189-195.
127. Voulgari PV, **Hatzimichael E**, Tsiara S, Tzallas C, Drosos AA, Bourantas KL. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes. *Eur J Haematol* 2001;66:31-36.
128. Makis AC, Chaliasos N, **Hatzimichael E**, Bourantas KL. Recombinant human erythropoietin therapy in a transfusion-dependent beta-thalassemia major patient. *Ann Hematol* 2001;80:492-495.
129. **Hatzimichael E**, Christou L, Bai M, Kolios G, Kefala L, Bourantas KL. Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenstrom's macroglobulinemia. *Eur J Haematol* 2001;66:1-6.
130. Christou L, **Hatzimichael E**, Chaidos A, Tsiara S, Bourantas KL. Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone. *Eur J Haematol* 2001;67:51-53.
131. Makis AC, **Hatzimichael E**, Mavridis A, Bourantas KL. Alpha-2-macroglobulin and interleukin-6 levels in steady-state sickle cell disease patients. *Acta Haematologica* 2000;104:164-168.
132. Makis AC, **Hatzimichael E**, Bourantas KL. The role of cytokines in sickle cell disease. *Ann Hematol* 2000;79:407-413.
133. Bourantas KL, Xenakis TA, **Hatzimichael E**, Kontogeorgakos V, Beris AE. Peri-operative use of recombinant human erythropoietin in Jehovah's Witnesses. *Haematologica* 2000;85:444-445.
134. Bourantas KL, **Hatzimichael E**, Makis AC, Kapsali E, Tsiara S, Christou L, Seferiadis K. Prolonged interferon-alpha-2b treatment of hairy cell leukemia patients. *Eur J Haematol* 2000;64:350-351.

135. Bourantas KL, **Hatzimichael E**, Tsiara, S. Elisaf, M. Konstantinidou, E. Xefteri, E. A patient with Down's syndrome and acute lymphoblastic leukemia who relapsed 20 years after first remission. *Haema* 2000;3.
136. **Hatzimichael E**, Bourantas K. L. Combination therapy with interferon-alpha-2b and hydroxyurea in patients with chronic myelogenous leukemia. *Eur J Intern Med* 1999;10:27-31.
137. Christou L, **Hatzimichael E**, Sotsiou-Candila F, Siamopoulos K, Bourantas KL. A patient with multiple myeloma, amyloidosis and light-chain deposition disease in kidneys with a long survival. *Acta Haematol* 1999;101:202-205.
138. Bourantas KL, **Hatzimichael E**, Makis AC, Chaidos A, Kapsali ED, Tsiara S, Mavridis A. Serum beta-2-microglobulin, TNF-alpha and interleukins in myeloproliferative disorders. *Eur J Haematol* 1999;63:19-25.